Novo Nordisk, a Danish pharmaceutical company, has grown from two early 20th-century insulin manufacturers into a global leader in diabetes care and obesity treatment. Its corporate history is marked by key scientific breakthroughs, strategic mergers, and international expansion.
August Krogh and Hans Christian Hagedorn found Nordisk Insulinlaboratorium to produce insulin for patients in Scandinavia. #pharma #diabetes
Brothers Harald and Thorvald Pedersen establish Novo Terapeutisk Laboratorium, initially producing a variety of pharmaceuticals alongside insulin. #pharma #biotech
Nordisk establishes Steno Memorial Hospital in Copenhagen, a specialized diabetes research and treatment center. #diabetes #healthcare
Hagedorn and colleagues develop Neutral Protamine Hagedorn (NPH) insulin, an intermediate-acting formulation that becomes a global standard. #diabetes #pharma
Novo Terapeutisk enters the enzyme business, developing microbial enzymes for industrial applications, a strategic diversification. #biotech #enzymes
Novo pioneers large-scale industrial production of insulin using bacterial fermentation, lowering costs. #pharma #biotech
Novo launches the first insulin pen injector, NovoPen, revolutionizing insulin delivery with convenience and accuracy. #diabetes #medtech
Novo receives approval for recombinant human insulin produced in yeast (Novolin), the first such product globally. #biotech #diabetes
Novo Industri A/S and Nordisk Gentofte A/S merge to form Novo Nordisk A/S, consolidating Danish insulin leadership. #pharma #merger
Novo Nordisk sets up a research center in China, expanding its global R&D footprint. #globalexpansion #pharma
NovoLet, a disposable prefilled insulin pen, is launched to enhance patient convenience. #diabetes #medtech
Novo Nordisk gains FDA approval for its recombinant human insulin in the United States. #FDA #diabetes
NovoRapid (insulin aspart) receives European approval, the first rapid-acting insulin analog. #diabetes #innovation
NovoRapid (Novolog) gets FDA approval for use in the United States. #FDA #diabetes
The company reorganizes into Diabetes Care, Biopharmaceuticals, and Enzyme Business to sharpen focus. #corporate #strategy
NovoSeven (recombinant factor VIIa) is approved to treat bleeding in hemophilia patients with inhibitors. #biotech #rareDisease
Levemir (insulin detemir) launches in Europe, a basal insulin analog with less weight gain. #diabetes #innovation
The FDA approves Levemir for glycemic control in adults with type 1 and type 2 diabetes. #FDA #diabetes
Novo Nordisk acquires a research facility in Seattle to expand biopharmaceutical R&D capacity. #biotech #R&D
Victoza (liraglutide), a GLP-1 receptor agonist, is approved in Europe for type 2 diabetes. #diabetes #GLP1
The FDA approves Victoza for type 2 diabetes, establishing Novo Nordisk in the GLP-1 market. #FDA #diabetes
Novo Nordisk inaugurates a large insulin production facility in Tianjin, China, to meet growing demand. #globalexpansion #manufacturing
Tresiba (insulin degludec), an ultra-long-acting basal insulin, gains European approval. #diabetes #innovation
The FDA approves Tresiba for diabetes, after a prior complete response letter in 2013. #FDA #diabetes
Ozempic (semaglutide), a once-weekly GLP-1 analog, is approved by the FDA for type 2 diabetes. #diabetes #GLP1
Rybelsus becomes the first oral GLP-1 receptor agonist approved for type 2 diabetes. #diabetes #innovation
FDA approves Rybelsus as the first oral GLP-1 therapy. #FDA #diabetes
Novo Nordisk acquires Emisphere Technologies to gain access to its oral delivery technology platform. #biotech #acquisition
Wegovy (semaglutide 2.4 mg) is approved for chronic weight management, launching Novo Nordisk into obesity care. #obesity #weightloss
Novo Nordisk announces positive phase 3 data for insulin icodec, a once-weekly basal insulin. #diabetes #innovation
Novo Nordisk marks 100 years since the founding of Nordisk Insulinlaboratorium, hosting global events. #pharma #anniversary
Novo Nordisk invests billions in expanding Ozempic production capacity to meet soaring global demand. #manufacturing #pharma